Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Protein aggregation in disease: a role for folding intermediates forming specific multimeric interactions
Arthur Horwich
Arthur Horwich
Published November 1, 2002
Citation Information: J Clin Invest. 2002;110(9):1221-1232. https://doi.org/10.1172/JCI16781.
View: Text | PDF
Perspective

Protein aggregation in disease: a role for folding intermediates forming specific multimeric interactions

  • Text
  • PDF
Abstract

Perspective

Authors

Arthur Horwich

×

Figure 3

Options: View larger image (or click on image) Download as PowerPoint
Protein misfolding and inclusion body formation studied in vivo with the...
Protein misfolding and inclusion body formation studied in vivo with the phage P22 system. (a) Crystal structure of a subunit of the P22 tailspike homotrimer (20), showing the parallel β-coil structure and ventral and dorsal “fins.” Blue spheres represent positions of temperature-sensitive folding mutants (21), which in general occupy solvent-exposed sites in this native form (see text). Two red spheres represent two global suppressor mutations (23). Reproduced with permission from The FASEB Journal (22). (b) Pathways of folding and aggregation in vivo of the phage P22 tailspike protein bearing temperature-sensitive folding mutations. The single-chain folding intermediates are thermolabile (designated I), with the mutations, potentially affecting turn formation, favoring off-pathway intermediate formation and association over productive folding. The global suppressor mutations reverse such partitioning, favoring the productive early folding intermediate over the aggregation-producing one (vertical arrow), even at 40°C. Reproduced with permission from Science (23). TSF, temperature-sensitive folding. (c) Folding and aggregation in vivo of phage P22 capsid protein bearing temperature-sensitive folding mutations (24). Pathways are similar to those for the tailspike. Here, the chaperonin system, GroEL/GroES/ATP, can act at 39°C to bind the aggregation-prone I* intermediate (monomer) and facilitate its productive folding. Reproduced with permission from The Journal of Biological Chemistry (24).

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts